biostudies-literatureUnknown9(28)Bendels MHK<h4>Background</h4>The present study aims to elucidate the success concerning gender equality in cancer research in the last decade (from 2008 to 2017) with prostate cancer as the target parameter.<h4>Results</h4>31.7% of all authorships and 36.3% of the first, 32.5% of the co- and 22.6% of the last authorships were held by women. The corresponding female-to-male odds ratio is 1.26 (CI: 1.22-1.30) for first, 1.15 (CI: 1.12-1.18) for co- and 0.59 (CI: 0.57-0.62) for last authorships. The annual growth rates are 0.6% overall and 0.9% for first, 0.2% for co-authorships, and 2.8% for last authorships. Women are slightly underrepresented at prestigious authorships compared to men. The female underrepresentation accentuates in articles with many authors that attract the highest citation rates. MOncotarget19640-19649https://www.ebi.ac.uk/biostudies/studies/S-EPMC5929414biostudies-literatureGendermetrics of cancer research: results from a global analysis on prostate cancer.PMC5929414Bendels MHKSchoffel NCostrut AMBruggmann DGroneberg DAfalseGendermetrics of cancer research: results from a global analysis on prostate cancer.<h4>Background</h4>The present study aims to elucidate the success concerning gender equality in cancer research in the last decade (from 2008 to 2017) with prostate cancer as the target parameter.<h4>Results</h4>31.7% of all authorships and 36.3% of the first, 32.5% of the co- and 22.6% of the last authorships were held by women. The corresponding female-to-male odds ratio is 1.26 (CI: 1.22-1.30) for first, 1.15 (CI: 1.12-1.18) for co- and 0.59 (CI: 0.57-0.62) for last authorships. The annual growth rates are 0.6% overall and 0.9% for first, 0.2% for co-authorships, and 2.8% for last authorships. Women are slightly underrepresented at prestigious authorships compared to men. The female underrepresentation accentuates in articles with many authors that attract the highest citation rates. M2018-01-01T00:00:00Z2018 Apr2026-07-16T13:24:25.67Z2025-06-01T00:15:28.804ZS-EPMC59294142973197110.18632/oncotarget.24716